Post by NEMERA

Transforming the GLP-1 Patient Experience Through Thoughtful Device Design As GLP-1 receptor agonist therapies continue to reshape the management of obesity and type 2 diabetes, the patient experience extends far beyond the drug itself. For many patients, long-term treatment success depends on a delivery device that is intuitive, comfortable, and reliable. This is where device design becomes a critical part of the therapeutic journey. At Nemera, we believe that pen injector solutions should be developed with patients at the center. From ease of use and injection confidence to ergonomic handling and adherence support, every detail matters—especially for patients managing chronic conditions that require regular self-administration. Our expertise in drug delivery systems enables us to support pharmaceutical partners with : 🔹 PenVARIO – A versatile manual variable-dose pen platform supporting intuitive dose setting, dose correction, and customization opportunities, making it suitable for chronic therapies, including GLP-1 applications. 🔹 PenDIA & PenSET – spring-assisted disposable pen platforms designed to simplify the injection experience through ease of use and precise dose delivery, helping reduce injection burden for patients managing weight loss and metabolic disorders. 🔹 PenDURA – A reusable, spring-assisted pen platform combining ergonomic design, low injection force, clear user feedback, and sustainability benefits to support long-term treatment adherence. As demand for GLP-1 therapies continues to grow globally, innovative delivery solutions will play an increasingly important role in helping patients stay on therapy and achieve better outcomes. Together, we can make the treatment journey simpler, more accessible, and more human-centered. 👉 Learn more about our pen injector solutions here: urlr.me/x9catZ Or contact us to discuss your program.